The approval was based on data from the phase 3 heiGHt trial, which compared Skytrofa to somatropin in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. Skytrofa ® ...
"We are delighted to have secured TGA registration of SKYTROFA for eligible Australian children with growth hormone deficiency. Beyond short stature, children and adolescents with the condition may ...
SKYTROFA ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency. [1] SINGAPORE, May 29, 2025 /PRNewswire/ -- ...
SKYTROFA ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency. [1] "We are delighted to have secured TGA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback